256 related articles for article (PubMed ID: 19136239)
1. Potential side effects in patients treated with inhaled corticosteroids and long-acting beta2-agonists.
Korsgaard J; Ledet M
Respir Med; 2009 Apr; 103(4):566-73. PubMed ID: 19136239
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Baker WL; Baker EL; Coleman CI
Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
[TBL] [Abstract][Full Text] [Related]
3. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
4. [Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].
Kimura T; Adachi M
Nihon Rinsho; 2001 Oct; 59(10):1992-9. PubMed ID: 11676144
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].
Beeh KM; Beier J; Kornmann O; Wiewrodt R; Buhl R;
Pneumologie; 2002 Feb; 56(2):91-7. PubMed ID: 11842346
[TBL] [Abstract][Full Text] [Related]
6. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis.
Foster JM; Aucott L; van der Werf RH; van der Meijden MJ; Schraa G; Postma DS; van der Molen T
Respir Med; 2006 Aug; 100(8):1318-36. PubMed ID: 16442275
[TBL] [Abstract][Full Text] [Related]
7. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
9. Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomized controlled trial.
Rowe BH; Wong E; Blitz S; Diner B; Mackey D; Ross S; Senthilselvan A
Acad Emerg Med; 2007 Oct; 14(10):833-40. PubMed ID: 17898245
[TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
11. Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.
Peters S
Curr Med Res Opin; 2007 Sep; 23 Suppl 3():S29-36. PubMed ID: 17925066
[TBL] [Abstract][Full Text] [Related]
12. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?
Sin DD; Man SF
Curr Opin Pulm Med; 2007 Mar; 13(2):90-7. PubMed ID: 17255798
[TBL] [Abstract][Full Text] [Related]
13. Inappropriate use of inhaled short acting beta-agonists and its association with patient health status.
Hong SH; Sanders BH; West D
Curr Med Res Opin; 2006 Jan; 22(1):33-40. PubMed ID: 16393428
[TBL] [Abstract][Full Text] [Related]
14. [Long-acting beta-2 agonists. An attempted response to various questions which can be posed by pneumonologists].
Vervloet D; Magnan A
Rev Mal Respir; 1998 Feb; 15(1):25-31. PubMed ID: 9551511
[TBL] [Abstract][Full Text] [Related]
15. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies.
Wise RA; Tashkin DP
Am J Med; 2007 Aug; 120(8 Suppl 1):S4-13. PubMed ID: 17678942
[TBL] [Abstract][Full Text] [Related]
16. Is there a problem with inhaled long-acting beta-adrenergic agonists?
Nelson HS
J Allergy Clin Immunol; 2006 Jan; 117(1):3-16; quiz 17. PubMed ID: 16387577
[TBL] [Abstract][Full Text] [Related]
17. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
Beeh KM; Beier J
Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
[TBL] [Abstract][Full Text] [Related]
18. Inhaled beta 2-adrenergic agonists in asthma: the evolving dilemma.
Hui KP
Singapore Med J; 1994 Jun; 35(3):237-9. PubMed ID: 7997893
[TBL] [Abstract][Full Text] [Related]
19. Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma.
Bijl-Hofland ID; Cloosterman SG; Folgering HT; van den Elshout FJ; van Weel C; van Schayck CP
Am J Respir Crit Care Med; 2001 Sep; 164(5):764-9. PubMed ID: 11549530
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma.
Kim D; Glaum M; Lockey R
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):933-40. PubMed ID: 19619072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
